Some examples include enasidenib for mutated isocitrate dehydrogenase 2 (IDH2) and Ivosidenib for mutated isocitrate dehydrogenase 1 (IDH1) in acute myeloid leukaemia (AML), 5-fluorouracil inhibiting Thymidylate synthase in gastric and breast cancer, and Methotrexate inhibiting dihydrofolate reductase (DHFR) in breast and lung cancer (58, 59). This evidence concerns the gene TYMS and acute myeloid leukemia.